AKT1 and alveolar rhabdomyosarcoma: Crizotinib pre-treatment for 4 h efficiently inhibited the IGF1-mediated stimulation of p-IGFIR with a parallel decrease of the known downstream effector p-AKT in both ARMS cell lines, without the respective total protein levels being perturbed (Fig. 6c).